Evolocumab Reduced Cardiovascular Risk After Bypass
A study found the drug lowered major cardiovascular events in patients who had bypass surgery but no prior heart attack.
Updated on Oct. 12, 2026 in Heart Disease
Live Poll
Should doctors aggressively use additional drug therapies to prevent future heart issues after bypass surgery?
Researchers determined that 140 mg of evolocumab administered every two weeks reduced major cardiovascular events in patients with prior coronary artery bypass grafting. These findings were presented in 2026 during the EACTS meeting in Barcelona.
Why it matters
Patients who have undergone bypass surgery without a previous myocardial infarction face elevated cardiovascular risks, making effective secondary prevention strategies critical. This study highlights a significant reduction in long-term complications for this specific population.
The study included 1,432 patients, showing a 56% reduction in LDL cholesterol and a 28% lower relative risk of four-point major cardiovascular events compared to placebo. A number needed to treat of 16 was required to prevent one event over the 4.5-year median follow-up.
The players
EACTS
The European Association for Cardio-Thoracic Surgery is a professional organization dedicated to the advancement of cardiovascular and thoracic surgical science.
The details
Participants randomized to receive 140 mg of evolocumab subcutaneously every two weeks saw their four-point MACE rate fall to 18.4%, compared to 24.6% in the placebo group. The study specifically monitored coronary heart disease death, myocardial infarction, ischemic stroke, and ischemia-driven revascularization.
Timeline
Findings were presented at the EACTS meeting in 2026.
The Big Picture
This research follows the precedent set by the FOURIER trial cardiovascular outcomes study by confirming LDL-lowering efficacy in specific high-risk subgroups.
Patients with a history of coronary artery bypass grafting should discuss these findings with their cardiologist to determine if PCSK9 inhibitors like evolocumab are appropriate for their lipid management plan. The treatment requires consistent subcutaneous administration to achieve the observed cholesterol-lowering and risk-reduction benefits.
The takeaway
This study underscores the value of aggressive lipid-lowering therapy for patients who have undergone bypass surgery even in the absence of a prior heart attack. Clinicians may consider these findings when tailoring cardiovascular risk reduction plans for high-risk surgical patients.
Further reading
For more on management strategies, explore the latest research in our Heart Disease section.
Source note: This article includes information reported by Tctmd.
Live Poll
Should doctors aggressively use additional drug therapies to prevent future heart issues after bypass surgery?
